On November 18, 2020, MedAvail, Inc., a healthcare technology company that embeds pharmacy services directly into clinics and other points of care, announced the completion of its previously announced business combination with MYOS RENS Technology, Inc., an advanced nutrition company focused on improving muscle health. Wilson Sonsini Goodrich & Rosati advised MedAvail in the transaction.
Under the terms of the merger agreement, which was previously announced on June 30, 2020, a wholly owned subsidiary of MYOS merged with and into MedAvail, with MedAvail becoming the surviving corporation and a wholly owned subsidiary of MYOS. The combined company will focus on the MedAvail business and its shares will trade on the Nasdaq Capital Market under the new trading symbol “MDVL.” The current MYOS RENS muscle health business will be spun off as a private unaffiliated company.
MedAvail currently deploys its MedCenter solution through two distinct commercialization channels: its SpotRx full-service retail pharmacy platform in the United States and its technologies channel in which it sells its MedCenter kiosk and licenses its proprietary software to large retailers and health systems. SpotRx currently has over 40 clinics deployed across Arizona and California.
The Wilson Sonsini team advising MedAvail includes the following attorneys:
Corporate
Philip Oettinger, Partner
Eric Hsu, Associate
Ryan Greecher, Partner
Joseph Chu, Senior Counsel
Brian Currie, Associate
Jeffrey You, Venture Counsel
Tax
Gregory Broome, Partner
Andrew Bryant, Senior Counsel
Jessica Yeh, Associate
Regulatory
Joshua Gruenspecht, Partner
David Hoffmeister, Partner
Eva Yin, Associate
Employee Benefits & Compensation
Scott McCall, Partner
Michael Klippert, Associate
Litigation
Katherine Henderson, Partner
Luke Liss, Senior Counsel
Mergers & Acquisitions
Ethan Lutske, Partner
Ross Tanaka, Associate
Please see MedAvail’s press release for more information.